An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance

(2022) Jiahui Chen et al.   Journal of Chemical Information and Modeling

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

(2021) Robert L. Gottlieb et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis

(2021) Bryan A. Johnson et al.   NATURE

Looking beyond COVID-19 vaccine phase 3 trials

(2021) Jerome H. Kim et al.   NATURE MEDICINE

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

(2021) Cheolmin Kim et al.   Nature Communications

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

(2021) Emma S. Winkler et al.   CELL

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

(2021) Zhuoming Liu et al.   Cell Host & Microbe

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

(2021) Pengfei Wang et al.   NATURE

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

(2021) Zijun Wang et al.   NATURE

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

(2021) Rita E. Chen et al.   NATURE MEDICINE

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

(2021) Constantinos Kurt Wibmer et al.   NATURE MEDICINE

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

(2021) Naveenchandra Suryadevara et al.   CELL

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

(2021) Bryan E. Jones et al.   Science Translational Medicine

A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope

(2021) Laura A. VanBlargan et al.   IMMUNITY

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

(2021) Rita E. Chen et al.   NATURE

Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies

(2021) Florian A. Lempp et al.   NATURE

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

(2021) Allison J. Greaney et al.   Nature Communications

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum

(2021) Wanwisa Dejnirattisai et al.   LANCET

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

(2021) Elisabetta Cameroni et al.   NATURE

Omicron likely to weaken COVID vaccine protection

(2021) Ewen Callaway   NATURE

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

(2021) Anil Gupta et al.   NEW ENGLAND JOURNAL OF MEDICINE

Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear

(2021) Ingrid Torjesen   BMJ-British Medical Journal

Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19

(2020) Gregory D. Sempowski et al.   CELL

A human neutralizing antibody targets the receptor binding site of SARS-CoV-2

(2020) Rui Shi et al.   NATURE

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

(2020) Dora Pinto et al.   NATURE

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

(2020) Jun Lan et al.   NATURE

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

(2020) Ruochen Zang et al.   Science Immunology

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

(2020) James Brett Case et al.   Cell Host & Microbe

Potently neutralizing and protective human antibodies against SARS-CoV-2

(2020) Seth J. Zost et al.   NATURE

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

(2020) Seth J. Zost et al.   NATURE MEDICINE

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

(2020) Alina Baum et al.   SCIENCE

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

(2020) Christopher O. Barnes et al.   NATURE

Spike mutation D614G alters SARS-CoV-2 fitness

(2020) Jessica A. Plante et al.   NATURE

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

(2020) Alina Baum et al.   SCIENCE

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

(2020) M. Alejandra Tortorici et al.   SCIENCE

Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality

(2020) Tomer Zohar et al.   CELL

A Crisp(r) New Perspective on SARS-CoV-2 Biology

(2020) Adam L. Bailey et al.   CELL

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

(2020) Alexandra Schäfer et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Direct visualization of translational GTPase factor pool formed around the archaeal ribosomal P-stalk by high-speed AFM

(2020) Hirotatsu Imai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

UCSF ChimeraX: Meeting modern challenges in visualization and analysis

(2017) Thomas D. Goddard et al.   PROTEIN SCIENCE